From the Food and Drug Administration.
Nightingale
S L
SL
D019386:Alendronate; D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D017291:Clarithromycin / Q000627:therapeutic use*; D003257:Consumer Product Safety; D004164:Diphosphonates / Q000008:administration & dosage / Q000009:adverse effects*; D017277:Drug Approval; D004359:Drug Therapy, Combination; D004381:Duodenal Ulcer / Q000188:drug therapy* / Q000382:microbiology; D004809:Ephedrine / Q000009:adverse effects*; D004935:Esophageal Diseases / Q000139:chemically induced*; D016481:Helicobacter Infections / Q000188:drug therapy* / Q000503:physiopathology; D016480:Helicobacter pylori; D013287:Illicit Drugs; D009853:Omeprazole / Q000627:therapeutic use; D010936:Plant Extracts / Q000009:adverse effects*; D011356:Product Labeling; D012008:Recurrence; D014481:United States; D014486:United States Food and Drug Administration
D000900:Anti-Bacterial Agents; D004164:Diphosphonates; D013287:Illicit Drugs; D010936:Plant Extracts; D004809:Ephedrine; D017291:Clarithromycin; D009853:Omeprazole; D019386:Alendronate